

## **BAB V**

### **KESIMPULAN dan SARAN**

#### **2.2 Kesimpulan**

- r. Berdasarkan hasil penelitian yang berjudul Studi Penggunaan Angiotensin Reseptor Bloker (ARB) pada Pasien Stroke Iskemik Rawat Inap di RSUD. Dr. Saiful Anwar Malang periode Januari 2013 sampai Juni 2013 diperoleh kesimpulan sebagai berikut :
- Penggunaan ARB tunggal sebanyak 2 pasien (11,1%), dengan jenis, dosis, frekuensi dan rute adalah valsartan (1x40mg) dan valsartan (1x80mg) secara oral masing-masing (50%).
  - Penggunaan ARB kombinasi dengan antihipertensi lain sebanyak 16 pasien (88,9%) dengan kombinasi, dosis, frekuensi, dan rute paling banyak adalah kombinasi ARB dengan CCB, yaitu valsartan (1x80mg) dan amlodipin (1x10mg) secara oral sebanyak 4 pasien (25%).
- s. Penggunaan obat golongan ARB yang diberikan pada pasien stroke iskemik rawat inap di RSUD. Dr. Saiful Anwar Malang, terkait dosis, rute, frekuensi, interval, dan lama pemberian sudah sesuai dengan *guidelines* (Sweetman, 2009) yang ada.

#### **2.3 Saran**

1. Diperlukan kelengkapan dari data Rekam Medik Kesehatan Pasien (RMK) sehingga dapat menunjang penelitian selanjutnya.
2. Penggunaan antibiotik seyogyanya mengikuti *guidelines* dan hasil dari kultur yang sudah ada untuk meningkatkan kualitas asuhan kefarmasian sebagai bagian dari tim pelayanan kesehatan guna meningkatkan kualitas hidup dari pasien.

## DAFTAR PUSTAKA

- Adams RD, Victor M, Rapper AH, 2003. *Cerebrovascular Disease, Principles of Neurology 6<sup>th</sup> ed.* New York City: McGraw-Hill Book.
- Adams R, Albers G, Alberts MJ, Benavente O, Furie K, Goldstein LB, Gorelick P, Halperin J, Harbaugh R, Johnston SC, Katzan I, Kelly-Hayes M, Kenton EJ, Marks M, Schwamm LH, Sacco RL, Tomsick T, 2008. **American Heart Association; American Stroke Association Council on Stroke; Council on Cardiovascular Radiology and Intervention; American Academy of Neurology. Update to the AHA/ASA Recommendations for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack Stroke**, 39:1647-1652.
- Adrian, J. G. and Louis R. C., 2011, **Esensial Stroke**, Penerbit Buku Kedokteran EGC, Jakarta, 83. Aminoff, MJ., 2009. Nerus System Disorders. In: McPhee, Stephen JJ., Papadakis, Maxine., **A Current Medical Diagnosis & Treatment**. The McGraw-Hill Companies: United States of America. Electronic version.
- Anna, Anastasia, Priambodo, A.P., Agustina, HR., 2007. Pengetahuan tentang Pencegahan Stroke pada Klien yang Mempunyai Faktor Resiko Terserang Stroke di Poli Penyakit Dalam Rumah Sakit Umum Daerah Garut. **Laporan penelitian Dosen Muda. Lembaga Penelitian Universitas Padjajaran.**
- Anonim, 2008. **BNF 56**. London : BMJ Group. Hal 111-117.
- Aziza, L., 2007. **Peran Antagonis Kalsium dalam Penatalaksanaan Hipertensi**. Maj Kedokteran Indonesia, Vol 57, No 8, Agustus 2007.
- Bahrudin, 2008, M., 2010. **Buku Ajar Kegawatan Neurologi**. Batu: Penerbit Cakrawala Indonesia, Hal 103-131.

- Becker, J.U., 2006. **Stroke Ischemic**. Availabel in [www.emedicine.com](http://www.emedicine.com)
- Bekki, H., Kiichiro, Y., Masayoshi, S., Tomoki, H., Masashi, N., Masatoshi, N., Kei, F., Seiya, & O., Sho-ichi, Y., 2010. **Efficacy of Combination Therapy with Telmisartan plus Amlodipine in Patients with Poorly Controlled Hypertension**. *Oxidative Medicine and Cellular Longevity* 3:5, 342-346.
- Budiarto, G., 2002. Stroke and Hypertention. *Dalam : Pendidikan Dokter Berkelanjutan, Update on Neurology*. Surabaya : Bagian Ilmu Penyakit Saraf Fakultas Kedokteran Universitas Airlangga/RSU Dr. Soetomo, hal. 1-9.
- Chaiyawat P., Kulkantrakorn K., 2012. Randomized Controlled Trial of Home Rehabilitation for Patients with Ischemic Stroke: Impact Upon Disability and Elderly Depression. **MEDLINE.**, Sep; 12(3):193-9
- Chobanian, A. V., Bakris, G.L., Black, H.R., Cusjman, W.C., Green,L.A., Izzo, J.L., Jones, D.W., Materson B.J., Oparil, S., and Wright, J.F., 2004. **The Seventh Report of The Joint National Committe on Prevntion, Detection, Evaluation, and Treatment of High Blood Pleasure**. *JAMA.*,The Complate Report, 94-97.
- Cheung, B., M., Y., 2004. **Sartans for hypertension–implications of the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial**. *Hong Kong Med J* Vol 10, p. 359.
- Chung, O., Csikos, T. & Unger, T., 1999. **Angiotensin II receptor pharmacology and AT1-receptor blockers**. *J.Human Hypertension* 13(suppl.1): S11-S20.
- Corwin and Elizabeth J., 2001. **Buku Saku Patofisiologi (Hnads Book of Pathophysiologi)**. Jakarta: EGC Hal. 76-77.
- Departemen Kesehatan Republik Indonesia, 2006, **Pharmaceutical Care untuk Hipertensi** hal. 28-32.

- Diwanto, Al, M., 2009. **Tips Mencegah Stroke, Hipertensi & Serangan Jantung**. Yogyakarta : Paradigma Indonesia, hal. 32-33.
- Dyker, A.G., Grosset, D.G., & Lees, K., 1997. **Peridopril reduces blood pressure but not cerebral blood flow in patients with recent cerebral ischemic stroke**. *Stroke* 28: 530-3.
- Evidence-Based Medicine Working Group, 1992. **Evidence-Based Medicine**: a new approach to practice of medicine. *JAMA*, 268:2420-2425.
- Fagan, S.C., and Hess, D.C., 2008. Stroke. In: DiPiro, J.T., Talbert, L., Yee, G.C., Matzke, G.R., Wells, B.G., and Posey, L.M., **Pharmacotherapy: A Pathophysiologic Approach**, Ed. 6<sup>th</sup>, United States of America: The McGraw-Hill Companies, Inc., p. 415-427.
- Gofir, A., 2009. **Manajemen Stroke**. Yogyakarta : Pustaka Cendekia Press, hal. 1-213.
- Goldstein, L.B., Adams, R., Alberts, M.J., Appel, L.J., Brass, L.M., Bushnell, C.D., Culebras, A., DeGraba, T.J., Gorelick, P.B., Guyton, J.R., Hart, R.G., Howard, Kelly-Hayes, G. M., Nixon, J.V., Sacco, R.L., 2011. **Primary Prevention of Ischemic Stroke: A Guideline from the American Heart Association/American Stroke Association. In: The American Academy of Neurology affirms the value of this guideline. United States of America : American Heart Association, Inc.** *Am Heart J.*, Vol 42, pp. 517-584.
- Goldszmidt, J.A., Louis, R.C., 2003. **Stroke Essentials**. Sudbury : Jones and Bartlett Publishers, Inc, p.1-130.
- Hankey, G.J., 2006. **Potential new risk factors for ischemic stroke: what is their potential?** *Stroke*, 37:2181-2188.

- Huang, Q.F., Chang, S.S., Yan, L., Gen, S.M., Qiu, Y.D., & Ji, G.W., 2013. **Efficacy and Safety of a Fixed Combination of Irbesartan/Hydrochlorothiazide in Chinese Patients with Moderate to Severe Hypertension.** *Drugs R D.* 13: 109-117.
- Indiana Stroke Prevention Task Force, 2006. Recommendations and Guidelines for: Recognition and Intervention of Risk Factors for Stroke, Diagnosis and Treatment of Transient Ischemic Attack, Diagnosis and Treatment of Ischemic Stroke.
- Irfan, M., 2010. **Fisioterapi Bagi Insan Stroke.** Yogyakarta : Graha Ilmu, hal. 60-61.
- Jannis, J., 2003. **Patofisiologi Stroke Iskemik**, dalam simposium new paradigma secondary prevention of stroke and other atherothrombotic events, Surabaya.
- Junaidi, Iskandar., 2011. **Stroke Waspadai Ancamannya.** Yogyakarta: ANDI Hal 71-72
- Kowalski, R.E., 2010. **Terapi Hipertensi: Program 8 Minggu Menurunkan Tekanan Darah Tinggi dan Mengurangi Risiko Serangan Jantung dan Stroke Secara Alami.** Bandung : Qanita, hal. 294-307.
- LaRue *et al.*, 1987. **Acute Stroke, Hematocrit, and Blood Pressure.** *Stroke*, 18:565-569.
- Lisabeth, Lynda PhD., Dr Bushnell, Cheryl MD., 2012. Stroke risk in women: the role of menopause and hormone therapy. **The Lancet Neurology.** Vol 11, Issue I, January 2012, Pages 82-91  
 Lloyd-Jones, D. M and Donnel, C. J., 2004. Hypertension As a Risk Factor for Stroke. *In:* Furie, K.L. and Kelly, P.J., **Handbook of Stroke Prevention in Clinical Practice.** New Jersey: HUMANA PRESS.

- Lumbantobing, S.M., 2001. **Neurogeriatri**. Jakarta : Balai Penerbit FKUI, hal. 93-133.
- Mansjoer, A., Suprohaita, Wardhani, W.L., Setiowulan, W., 2007. **Kapita Selekta Kedokteran**. Fakultas Kedokteran Universitas Indonesia, Jakarta. 17-26.
- Martiani, Ayu. 2012. **Faktor Resiko Hipertensi Ditinjau Dari Kebiasaan Minum Kopi**. Tesis : Program Studi Ilmu Gizi Fakultas Ilmu Kedokteran Universitas Diponegoro
- McClellan, KJ. & Goa, KL., 1998. **Candesartan colexetil: a review of its use in essential hypertension**. *Drug* 56(3): 847-69.
- Mc Evoy, G.K, 2008. **AHFS Drug Information Book I**, United States of America: American Society of Health System Pharmacist, Electronic version.
- Misbach, J., Airiza, A., Lyna, S., Jofizal, J., Salim, H., Silvia, L., Al, R. & Enny, M., 2007. **Pandangan Umum mengenai Stroke**. Jakarta : Balai Penerbit FKUI, hal. 1-9.
- Miyazaki, M., Wada, T., Shiota, N. & Takai, S., 1999. **Effects of an angiotensin II receptor antagonist, candesartan cilexetil, on canine intima hyperplasia after balloon injury**. *J.Hum Hypertens*. 13(suppl.1): S21-5; discussion S33-4.
- Nafrialdi, 2007. **Farmakologi dan Terapi**. Edisi 5. Badan Penerbit FKUI, Jakarta. Hal 358-360.
- Pedelty, L and Gorelick, P. B., 2004, **Chronic management of Blood Pressure after stroke**. *Hypertension*, 44.
- PERDOSSI, 2007. **Guideline Stroke**. Jakarta : Perhimpunan Dokter Spesialis Saraf Indonesia. Hal 7-9.

- PERDOSSI., 2004. **Guideline Stroke**. Jakarta: Perhimpunan Dokter Spesialis Saraf Indonesia. Hal.914
- Pujihastuti, A. 2008. **Analisis Tingkat Kepuasan Pasien Askeskin, Askes PNS, Umum pada Pelayanan Loker Pendaftaran Rawat Jalan di RSUD Kabupaten Karanganyar**. Skripsi : Program Studi Kesehatan Masyarakat Fakultas Ilmu Kesehatan Universitas Muhammadiyah Surakarta.
- Qureshi *et al.*, 2005. Cigarette smoking among spouses: **Another risk factor for stroke in women**. *Stroke*, 36:e74-e76.
- Ridwan, M., 2002. **Mengenal, Mencegah, Mengatasi Silent Killer, “Hipertensi”**. Semarang : Pustaka Widayama, hal. 1-41.
- Ripley, E., & Ari, H., 2010. **Fifteen years of losartan: what have we learned about losartan that can benefit chronic kidney disease patients?** International Journal of Nephrology and Renovascular Disease. Vol. 3, pp.93-98.
- Rothwell, P.M., Howard, S.C., Power, D.A., Gutnikov, S.A., Algra, A., Van, G.J., Clark, T.G., Murphy, M.F., Warlow, C.P., 2004. **Fibrinogen concentration and risk of ischemic stroke and acute coronary events in 5113 patients with transient ischemic attack and minor ischemic stroke**. *Stroke*, 35:2300-2305.
- S., Wiwit., 2010. **Stroke & Penanganannya: Memahami, Mencegah, & Mengobati Stroke**. Jogjakarta : Katahati, hal. 13-49.
- Sacco, R.L., Emelia, J.B., Joseph, P.B., Mark, D., J.Donald, E., Phillip, B.G., George, H., Steven, J.K., Teri, A.M., Jack, P.W., and Philph, A.W., 1997. Committee and Stroke Statistics Subcommittee, **Am Heart J.**, Vol 28, PP. 1507-1517.
- Sacco, R. L., Adam, R., Chair, V., Albers, G., Alberts, M. J., Benavente, O., Furie, K., Goldstein, L. B., Gorelick, P., Halperin, J., Harbaugh, R., Johnston, S. C., Katzan, I., Kelly-Hayes, M., Kenton, E. J., Marks, M., Schwamm, L. H., Tomsick, T., 2006. **Guidelines for Prevention of Stroke in Patients With Ischemic Stroke or Transient Ischemic Attack. A Statements for Healthcare**

**Professionals From The American Heart Association/ American Stroke Association Council on Stroke. *Stroke*, 37:577-617**

- Sever, P., 1997. **Candesartan Cilexetil : a new, long-acting, affectives angiotensin II tipe I receptor blockers.** *J.Hum.Hypertens.* 13(suppl.1): S3-S10.
- Siswando, Dr., Apt., M.S., 2008. **KIMIA MEDISINAL.** Airlangga University Press, Hal 109-161; 309-351.
- Smit, Wade S., English, Joe D., Johnston, S., and Claiborn., 2008. Cerebrovaskular diseases. *In:* Fausi., Kasper., Longo, Braunwald., Hayser., Jamesom, Loscalzo. **Herrison's Principles of Internal Medicine.** ED 7<sup>th</sup>/ The McGraw-Hill Companies, Inc: United States of America. Electronic version.
- Soemantri, D., and Nugroho, J., 2006. Hipertensi. **Standar Diagnosis dan Terapi Penyakit Jantung dan Pembuluh Darah** Ed.4 editor: Mochammad Soetomo, Achmad Lefi Hal. 36-38.
- Sweetman, S., 2009. Martindale 36 : **The Complete Drug Reference.** Britain: Pharmaceutical Press, Electronic version.
- Sylvia, A. P., and Lorraine M. W., 2006, **Patofisiologi : Konsep Klinis Proses-Proses Penyakit,** Volume 2, Edisi 6, Penerbit Buku Kedokteran EGC, Jakarta, 1106:1117.
- Tatro, D.S., 2008. **A to Z Drug Facts and Comparison.** Electric version, Book@Ovid.
- Utama, H., Herqutanto, 2008. **Tekanan Darah Tinggi.** Jakarta : Balai Penerbit FKUI, hal. 1-46.

- Victor, M. & Ropper, AS.H., 2001. Principles of Neurology. 7 th ed McGraw-Hill, New York.
- Wang, Guang Ji, 2009. **A Combined Role of Calcium Channel Blockers and Angiotensin Receptor Blockers in Stroke Prevention.** Centre for Epidemiological Studies and Clinical Trials, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
- WHO, 1988. **Task Force on Stroke and other Cerebrovascular Disorder.** America: World Health Organization
- Wibowo, S. & Abdul, G., 2001. **Farmakoterapi dalam Neurologi.** Jakarta : Salemba Medika, hal. 53- 71.
- Widjaja, D.2007. Perkembangan Mutakhir Management Stroke Iskemik. Dalam : **Pendidikan Dokter Berkelanjutan, Update on Neurology.** Surabaya: Bagian Ilmu Penyakit Saraf Fakultas Kedokteran Universitas Airlangga/ RSUD Dr. Soetomo, pp 1-40.